Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide With or Without Abiraterone Acetate as Neoadjuvant Therapy for High-Risk Prostate Cancer
NCT02268175Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Abiraterone Acetate Tablets (I) in prostate cancer (PCa), sponsored by Dana-Farber Cancer Institute. Started Oct 2014; status: completed.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02268175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268175.